


# Life Settlement Assets PLC – Ordinary Share A

## Investment Objective

The company’s investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

## Estimated Performance

	Feb	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Dec	Dec	YTD	Roll. 12M
Est. Performance (%) 2024	-1.06%	6.87%	-0.86%	-0.64%	-0.79%	-0.22%	2.44%	-0.58%	-0.85%	0.31%			4.32%	9.52%



## Commentary

**Investment Terms**  
1.5% Management Fee

**Estimated NAV (USD)**  
106 088 705

**NAV/Share**  
2.3112

A new study reveals that the rapid life expectancy gains of the 20th century have slowed dramatically, with U.S. life expectancy even declining. Analysing data from nine of the world's longest-lived regions, researchers found that from 1990 to 2019, average life expectancy increased by only 6.5 years, compared to an earlier trend of gaining three years per decade. The study suggests that only 5.3% of girls and 1.8% of boys born recently in these regions are likely to reach 100 years old, highlighting a "biological ceiling" for lifespan. Experts argue that to further extend life expectancy, radical new treatments targeting the aging process itself are needed rather than treatments for individual diseases. While some researchers, like Steven Austad, remain optimistic that advances in geroscience could enable significant life extension, others are cautious, projecting a continued slowdown in longevity improvements without breakthroughs in anti-aging therapies.

The Share Class is reporting a performance of 0.31% for the month of October. Seven HIV maturities were registered, contributing a total Death Benefit of \$0.4M; four maturities for a total face value of \$2.0M were registered in the non-HIV segment this month.

Number Of Policies	Net Death Benefits (USD)	Matured Policies YTD	Maturities YTD (USD)
3 822	413 682 206	96	21 481 889

**Trust Investment Manager** Acheron Capital Ltd.







**Administrator** Compagnie Européenne de Révision

**Auditor** BDO UK LLP

**Company Secretary** ISCA Administration Services Limited


**ISIN** GB00BF1Q4B05  
**Ticker** LSAA

**Info** life@acheroncapital.com  
+44 207 258 5990



(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.  
 (2)Distribution by issue dates reflects the time since the life insurance policy was issued.  
 Source of Data: Acheron Capital Ltd unless otherwise stated.


## Historical Maturity



## Maturities October 2024

Number of policies matured in October 2024	11
Corresponding number of insured	7
Total death benefit in October 2024 (US\$)	2 431 398
Valuation of Matured policies (US\$)	523 407

## Notification of Maturity



## Premiums Situation (US\$) <sup>(1)</sup>

Servicers Premiums Projection for the next 12 months	\$ 14.0M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 13.5M
Estimated COI Net of Mortality for the next 12 months	\$ 13.0M

## Top 10 Coverage

Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	7.2	7.2	99	110
2	2.0/1.0/1.0/0.9/0.3	5.2	96	100/100/100/100/100
3	3.0	3.0	95	100
4	3.0	3.0	68	90
5	1.5/1.0/0.3	2.8	93	100/100/100
6	2.8	2.8	93	100
7	2.0	2.0	90	110
8	2.0	2.0	104	120
9	1.0/0.5	1.5	68	100/100
10	0.1/0.1/0.059/0.35/0.15/0.1/0.1/0.06/0.1/0.1	1.2	70	100/100/100/95/95/70/100/95/100/100

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

\*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.